Article

Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

Author(s):

Bonnie Gillis

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Click here to view the full-text version of this article.

Related Videos
Country-Level Socioeconomic Status, Healthcare Impact AKI Outcomes in Cirrhosis
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Related Content
Psoriasis Severity, Systemic Inflammation Associated with Cardiovascular Disease
November 23rd 2024

Psoriasis Severity, Systemic Inflammation Associated with Cardiovascular Disease

Tim Smith
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Gildeuretinol for Stargardt Secures FDA Rare Pediatric, Fast Track Status | Image Credit: Vitreo Retinal Associates
November 22nd 2024

Gildeuretinol for Stargardt Secures FDA Rare Pediatric, Fast Track Status

Connor Iapoce
Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence
November 22nd 2024

Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.